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Research Statement 
What is already known? 
• Diabetic eye disease is a leading cause of preventable vision loss. 
• Diabetic eye disease is negatively associated with health-related quality of life. 
What are the new findings? 
• There is considerable impact to visual functioning which is more impaired in people with 
greater disease severity. 
• Diabetic eye disease limits activities including working, driving, walking and reading. 
• Vision loss in diabetic retinopathy has the potential to negatively impact psychological well-
being. 
How might this impact on clinical practice in the foreseeable future?  
• The review shows the importance in clinical practice to measure and consider the everyday 
impacts of diabetic retinopathy and diabetic macular oedema, which include psychological 
well-being, functional status, quality of life, and impacts on work. 
Abstract 
Aims 
To synthesise evidence on the impact of diabetic retinopathy and diabetic macular oedema from the 
patient perspective. 
Methods 
A systematic literature review was conducted using MEDLINE Complete, PsycINFO, EMBASE, and 
AMED. We included articles investigating the impact of the condition on quality of life, symptoms, 
visual functioning, activities of daily living, well-being, social, and financial. Studies were 
observational; cross-sectional, prospective cohort and retrospective cohort study designs. Outcome 
data were extracted and synthesised. The review is registered on PROSPERO (CRD42018088254).  
Results 
Searches yielded 5114 publications. After screening, 85 studies were included, measuring the 
following outcomes: visual functioning (n=41), quality of life (n=23), well-being (n=16), functional 
status (n=14), work (n=2), and visual task performance (n=2). Diabetic retinopathy has a 
considerable impact on visual functioning, which is greater in people with greater disease severity. 
Diabetic retinopathy significantly limits activities including working, driving, walking and reading and 
has the potential to negatively impact psychological well-being. 
Conclusions 
Diabetic retinopathy is associated with poor self-reported visual functioning, well-being, and health-
related quality of life. Ability to perform basic everyday tasks appears to diminish with disease 
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severity. Some studies suggest impaired mobility and problems with work but there are gaps in this 
evidence.  
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Introduction 
Diabetic eye disease is a leading cause of preventable vision loss in working age people [1], affecting 
approximately one third of individuals with diabetes worldwide [2]. It is responsible for 6.4% and 
5.3% of sight impairment and severe sight impairment registrations respectively, in England and 
Wales [3]. Diabetic eye disease can be broadly classified into non-proliferative diabetic retinopathy, 
characterised by microaneurysms, intraretinal haemorrhages, venous beading or intra retinal 
microvascular abnormalities, and proliferative diabetic retinopathy, characterised by retinal 
neovascularisation. Diabetic maculopathy occurs when the macula is affected; this most commonly 
manifests as diabetic macular oedema (DME), where central vision loss results from thickening of 
the macula [4]. Proliferative diabetic retinopathy indicates greater severity of diabetic retinopathy in 
comparison to non-proliferative diabetic retinopathy, and proliferative diabetic retinopathy and 
DME are both considered sight-threatening forms of diabetic retinopathy. 
As the number of people with DME and diabetic retinopathy increases [5-8], driven in part 
by increased longevity, it is important to understand the impact that these conditions have on the 
individual. This includes their everyday visual and functional abilities (i.e. ability to perform activities 
of daily living), psychological well-being, social functioning and quality of life. Reviews of the 
literature suggest that people with diabetic retinopathy experience poor health-related quality of life 
[9], particularly in the vision-threatening stage of the condition [10]. Reviews specific to DME are 
limited, but also suggest reduced vision and health-related quality of life [11]. These reviews have 
however, focused only on health or vision-related quality of life rather than explore the full 
spectrum of possible impact, lacked rigorous systematic review methodology and are limited by the 
lack of empirical evidence at the time of their publication. We hypothesise that there are other real-
world impacts of importance in diabetic retinopathy and DME that previous reviews have not 
reported.  
The aim of this systematic review is to therefore synthesise current evidence on the 
psychological, social, and everyday visual impact of DME and diabetic retinopathy from the patient 
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perspective. We aim to provide insight into the everyday lives of people with diabetic retinopathy 
and DME, by synthesising the impact of these conditions on psychological well-being, functional 
status, performance in everyday tasks, quality of life, work and visual functioning. This is the first 
review to integrate existing literature from all of these domains. 
Participants and Methods 
A systematic literature review was conducted in in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12] and the Guidance on the 
Conduct of Narrative Synthesis in Systematic Reviews [13]. The study is registered on the PROSPERO 
database, registration number CRD42018088254.  
Participants 
Adults (aged 18 years or older) with any form of diabetic eye disease, including all severities of non-
proliferative retinopathy, maculopathy, and proliferative retinopathy.   
Interventions or Comparators 
This systematic review did not evaluate the effectiveness or efficacy of interventions or treatments 
for diabetic eye disease. Interventional studies were included in the review, but only to extract 
baseline data for the relevant outcomes. The included studies could be a single group design or 
include a comparison group, for example those with vision loss from another condition, the general 
population or those with diabetes but without diabetic eye disease.  
Outcome 
The systematic review aimed to assess the impact of diabetic eye disease from the patient 
perspective in relation to the following outcomes: 
• Quality of life, including generic and health-related quality of life 
• Symptoms, such as pain 
• Self-reported visual disturbance 
• Activities of daily living, such as loss of driving licence and physical functioning  
• Psychological well-being, such as depression and anxiety 
• Social impact on family relationships, and participation in social activities 
• Economic impact; financial costs to patient, loss of earnings, absence or inability to work, 
work productivity, employment  
These outcomes could be measured using validated or unvalidated scales, using either patient-
reported, observer-reported or performance-based tools. The review excluded studies in which the 
only outcomes were utility values for health economic modelling purposes.  
Study Type 
Included studies were observational, which included cross-sectional, prospective cohort and 
retrospective cohort study designs. When observational studies included multiple assessment time 
points, all points were considered. Randomised controlled trials and quasi-experimental studies 
were included to extract the relevant data at baseline. Qualitative and case studies were excluded. 
All articles had to be published in peer-reviewed scientific journals and in English.  
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Search Strategy 
The literature search was conducted in MEDLINE Complete, and PsycINFO (via EBSCOhost), and 
EMBASE, and AMED (via OVID) from inception to 31st January 2018. Medical subject heading (MeSH) 
terms were used to identify the most relevant articles (example shown of MEDLINE MeSH terms in 
appendix). Reference lists of included studies and any identified systematic reviews were also 
reviewed for relevant articles.  
Studies were screened for inclusion using Covidence, a computerised literature review extraction 
software. Search results were imported directly into Covidence, where duplicates were removed. 
The title and abstract for each article were screened by two authors independently, followed by the 
full text articles of those deemed to be relevant. Any disagreements at either stage were discussed 
until consensus was reached, with a third reviewer acting as an adjudicator if needed.  
Data analysis 
The following information was extracted from the journal articles independently by the two 
reviewers; citation, study country, study type, study institution/sponsor, study objectives, study 
inclusion/exclusion criteria, sample size, study duration, participant characteristics (gender, age, 
disease type, treatment history, disease duration, disease severity, diabetes type, duration of 
diabetes), outcomes measured, results for each outcome, and overall conclusions. Study quality was 
assessed independently by two authors, using the 14-item standard quality assessment for 
evaluating primary research papers from a variety of fields [14]. Total scores range from 0 to 1 with 0 
indicating the lowest and 1 the highest possible quality. Scores exceeding 0.55 or 0.75 may be 
considered acceptable, depending on whether a ‘liberal’ or ‘conservative’ viewpoint is taken [14]. 
Any item level disagreements were discussed until consensus was reached, with a third reviewer 
acting as an adjudicator if needed. 
Results 
The search yielded a total of 5114 publications.  After duplicates were removed and studies were 
screened at abstract and full text level, 85 studies were deemed eligible for inclusion in the review 
(Figure 1). Details of each study included, including a summary of data extracted and quality 
appraisal scores can be found in Table 1. Mean quality appraisal score was 0.84 (standard deviation 
±0.13, range 0.32 to 1.00). Depending on the threshold used, either 2 studies (using liberal 
threshold) or 15 studies (using conservative threshold) fell outside acceptable limits for quality 
scores. Most frequent sources of bias were related to failing to control for confounding (22% of 
studies) and failing to report some estimate of variance for main results (9% of studies). Studies 
were conducted across 21 countries, the most frequent of these were: USA (n=27); Australia (n=11); 
UK (n=6); Japan (n=5); Sweden (n=5); Singapore (n=4); Spain (n=4); Turkey (n=4). The majority of 
studies were of a cross-sectional design (n=49). Other designs included clinical trials and 
interventional studies (n=17), case control (n=5), cohort (n=12), and case series (n=4). In the 78 
studies that reported their sample size the number of people with diabetic retinopathy ranged from 
8-1097.  The samples were either exclusively people with diabetic retinopathy or DME (n=55); other 
samples consisted of people with diabetes (n=16), and people with other conditions which included 
diabetic retinopathy (n=14). 
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Participant Characteristics 
The proportion of male participants ranged from 18-75% in the 73 studies that reported this 
characteristic. Of the 70 articles in the review that reported age, mean age ranged from 29-77 years. 
Fewer than half of the studies reported diabetes duration (n=39). Durations were reported as time 
since diagnosis using median, mean, and percentage above, in or below certain age ranges. Mean 
disease duration ranged from 3 years to 39 years.  
Outcomes 
Results are organised according to the following outcomes: self-reported visual functioning (n=41), 
quality of life (n=23), psychological well-being (n=16), functional status (n=14), work (n=4), and visual 
task performance (n=3), using 51 different outcome measures. These six categories were based on 
groupings previously put forth by Mitchell and Bradley [15]. Forty-eight of these were patient 
reported outcome measures and 3 performance based or objective measures. Details of study 
characteristics by outcome are shown in Table 2.  
Studies were categorised in the review into psychological well-being if they included measures of 
mood, depression, and/or anxiety. Functional status studies were those that investigated a person’s 
ability to carry out tasks of daily living, not specific to vision.  Articles were grouped into visual task 
performance if they included objective outcomes that measured performance of vision-related 
tasks. Quality of life studies were those that measured components relevant to quality of life. Work 
studies included those that measured the impact on work, education and/or employment. Studies 
were grouped into self-reported visual functioning if they measured self-reported ability to perform 
vision-related tasks including reading, writing, recognising faces, watching television or driving. 
Psychological Well-Being 
Summary 
Seventeen studies explored the psychological well-being of individuals with diabetic retinopathy 
using 19 different measures (Rees et al., 2017, Sahni et al., 2017, Rees et al., 2016, Karlson and 
Agardh, 1997, Sinzato et al., 1985, Rees et al., 2012, Xu et al., 2015, Jacobson et al., 1985, Wulsin et 
al., 1993, Wulsin et al., 1991, Bernbaum et al., 1988, Williams and Ponchillia, 1998, Hirai et al., 2012, 
Le Floch et al., 2014, Upton et al., 1998, Saglam et al., 2010). All were patient reported outcome 
measures, 17 were generic measures (Rees et al., 2017, Sahni et al., 2017, Rees et al., 2016, Karlson 
and Agardh, 1997, Sinzato et al., 1985, Rees et al., 2012, Xu et al., 2015, Jacobson et al., 1985, Wulsin 
et al., 1993, Wulsin et al., 1991, Bernbaum et al., 1988, Williams and Ponchillia, 1998, Hirai et al., 
2012, Le Floch et al., 2014, Upton et al., 1998, Saglam et al., 2010), and two were specific to diabetes 
(Rees et al., 2017, Bernbaum et al., 1988). Seventeen of the measures had shown previous validity 
and 4 of the measures showed negligible to no validity in any population. Study quality ranged from 
0.55 to 1.00.  
Impact of presence of diabetic retinopathy  
After controlling for potential confounders, people with diabetic retinopathy were at greater risk of 
experiencing symptoms of anxiety and depression (Rees et al., 2012, Le Floch et al., 2014) and were 
more poorly adjusted to living with their condition (Wulsin et al., 1993, Bernbaum et al., 1988) than 
people with diabetes, but without diabetic retinopathy.  
Impact of diabetic retinopathy severity 
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Findings about diabetic retinopathy severity and its relationship with depression and anxiety were 
mixed. Two correlational studies found that greater diabetic retinopathy severity was associated 
with increased symptoms of depression (Rees et al., 2016) and trait as opposed to state anxiety 
(Sinzato et al., 1985). Other studies however, failed to replicate these findings for depression (Hirai 
et al., 2012, Karlson and Agardh, 1997, Xu et al., 2015).  
Increased depressive symptoms were associated with worse diabetic retinopathy severity in 
terms of worse visual acuity (Williams and Ponchillia, 1998, Xu et al., 2015). Worse visual acuity 
resulting from diabetic retinopathy was also associated with poor adjustment and negative 
psychological symptoms (Wulsin et al., 1993, Wulsin et al., 1991) in individuals with stable vision, but 
not in those with recent vision loss (Wulsin et al., 1993).  
Functional Status 
Five studies reported on functional status in diabetic retinopathy (Gupta et al., 2017, 
Agrawal et al., 2010, Le Floch et al., 2014, Upton et al., 1998, Ivers et al., 1998), with four generic 
patient reported outcome measures used. Study quality ranged from 0.55 to 0.91.  
The activities of daily living scale showed no significant associations in impairments of 
activities of daily living between individuals with diabetes without diabetic retinopathy, non-
proliferative diabetic retinopathy, and proliferative diabetic retinopathy. However, significant 
differences were seen for instrumental activities of daily living between these groups, with the 
greatest impairment seen in proliferative diabetic retinopathy (Le Floch et al., 2014). Another study 
showed people with diabetic retinopathy had significantly more problems in instrumental activities 
of daily living in comparison to non-diabetic people with other types of vision loss (Upton et al., 
1998).  
Results regarding falls were mixed. Two studies reported no association between diabetic 
retinopathy and risk of falling (Agrawal et al., 2010, Ivers et al., 1998). In contrast, another study 
reported that individuals with mild or moderate diabetic retinopathy had significantly elevated odds 
of falling in comparison to people with diabetes but without diabetic retinopathy (Gupta et al., 
2017).  
Visual Task Performance 
Three studies objectively investigated performance of everyday tasks in people with diabetic 
retinopathy (Warrian et al., 2010, Warrian et al., 2015, Szlyk et al., 2004). Study quality ranged from 
0.55 to 0.95.  People with diabetic retinopathy made significantly more errors and took longer to 
complete a mobility course in comparison to healthy volunteers. Another study found no association 
between driving performance on an interactive simulator and diabetic retinopathy severity. 
However, focal laser scars were significantly associated with poorer performance on the driving 
simulator in this sample (Szlyk et al., 2004).  
Quality of Life 
Summary 
The review identified 23 studies assessing quality of life using 11 different outcome 
measures (Ahola et al., 2010, Alcubierre et al., 2014, Brose and Bradley, 2010, Bujang et al., 2017, 
Daher et al., 2015, Davidov et al., 2009, Esteban et al., 2008, Fenwick et al., 2017, Granado-Casas et 
al., 2017, Granstrom et al., 2015, Hannula et al., 2014, Hirai et al., 2013, Hui et al., 2017, Jiao et al., 
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2017, Leksell et al., 2005, Wang et al., 2012, Mazhar et al., 2011, Ramu et al., 2017, Scanlon et al., 
2015, Sepulveda et al., 2015, Venkataraman et al., 2013, Wu et al., 2016, Xu et al., 2015). Seven of 
the patient reported outcome measures used were generic, two specific to diabetes, and two 
diabetic retinopathy specific. Study quality ranged from 0.82 to 1.00. Although the majority of 
quality of life studies were cross-sectional or cohort in design, two studies were interventional using 
quality of life as endpoints to measure efficacy of treatment (Ramu et al., 2017, Wu et al., 2016). 
Impact of presence of diabetic retinopathy 
Poorer overall quality of life was seen in individuals with diabetic retinopathy along with 
significantly poorer physical functioning, general health, and vitality compared with people with 
diabetes but without diabetic retinopathy (Alcubierre et al., 2014, Daher et al., 2015, Granado-Casas 
et al., 2017). Conversely, three studies showed that diabetic retinopathy was not associated with 
poorer quality of life in comparison to people with diabetes but without diabetic retinopathy (Ahola 
et al., 2010, Bujang et al., 2017, Sepulveda et al., 2015). In comparison to the general population and 
samples without any diabetes, diabetic retinopathy was associated with poorer quality of life in 
some studies (Esteban et al., 2008, Hui et al., 2017, Jiao et al., 2017), but not others (Lin and Yu, 
2012). 
Impact of diabetic retinopathy severity 
The impact of disease severity on quality of life was mixed. Whilst one study found no 
differences between proliferative and non-proliferative diabetic retinopathy in generic quality of life, 
diabetes-specific quality of life was significantly worse in the proliferative diabetic retinopathy group 
(Brose and Bradley, 2010). Similarly, significantly worse general quality of life was found amongst 
individuals with proliferative diabetic retinopathy in comparison to those with less severe diabetic 
retinopathy or no diabetic retinopathy (Hannula et al., 2014) and greater severe disease severity was 
associated with poorer physical health quality of life, but not mental health quality of life (Mazhar et 
al., 2011, Venkataraman et al., 2013). Other studies however, showed no significant associations 
between diabetic retinopathy severity or visual impairment and quality of life (Granstrom et al., 
2015, Hirai et al., 2013). 
Poorer visual acuity was associated with significantly poorer quality of life in people with 
diabetic retinopathy (Davidov et al., 2009, Leksell et al., 2005, Scanlon et al., 2015, Xu et al., 2015).  
Work 
Four studies explored the impact of diabetic retinopathy on work (Abraldes et al., 2016, 
Davidov et al., 2009, Beaulieu et al., 2016, Brook et al., 2015). Study quality ranged from 0.83 to 
0.95. People with diabetic retinopathy reported impaired work over the previous 7 days due to their 
vision 20-23% of the time (Beaulieu et al., 2016). Using an unvalidated questionnaire (Abraldes et al., 
2016) 4.3% of respondents with DME had reduced their working hours, 1.2% had to switch 
jobs/careers, 1.5% had lost their job, 6.7% decreased their economic income, 5.1% had to quit their 
job, and 6.3% had been granted or requested a disability pension in the past 3 months due to their 
condition. One study reported 17.4% of their sample had a reduction in earning capacity due to 
diabetic retinopathy (Davidov et al., 2009). Another study used figures taken from the Human 
Capital Management Services Group Research Reference Database completed by businesses (Brook 
et al., 2015); workers with diabetic retinopathy were absent from work for significantly more days in 
comparison to controls without diabetes; there were no differences between people with DME and 
people with diabetic retinopathy. 
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Self-Reported Visual Functioning 
Summary 
Visual functioning in diabetic retinopathy was reported by 46 studies using 11 different 
outcome measures (Ahmadian and Massof, 2008, Aroney et al., 2016, Bailey and Sparrow, 2001, 
Beaulieu et al., 2016, Bertelmann et al., 2016, Bressler et al., 2016, Bressler et al., 2014, Broman et 
al., 2002, Cetin et al., 2012, Gabrielian et al., 2010, Gillies et al., 2014, Granstrom et al., 2015, 
Hariprasad et al., 2008, Henricsson and Heijl, 1994, Hui et al., 2017, Jannuzzi et al., 2014, Kamel et 
al., 2000, Kishimoto and Ohtsuki, 2012, Klein et al., 2001, Lamoureux et al., 2010, Lamoureux et al., 
2004, Lin and Chie, 2010, Lin and Yu, 2012, Lloyd et al., 2013, Loftus et al., 2011, Man et al., 2016, 
Matza et al., 2008, Mazhar et al., 2011, Mitchell et al., 2013, Nilsson, 1986, Okamoto et al., 2008, 
Okamoto et al., 2010, Okamoto et al., 2014, Pereira et al., 2017, Ramu et al., 2017, Ratanasukon et 
al., 2016, Scanlon et al., 2015, Toprak et al., 2005, Trento et al., 2017, Trento et al., 2013, Tsilimbaris 
et al., 2013, Turkoglu et al., 2015, Vijayan et al., 2017, Warrian et al., 2010, Willis et al., 2017, Hirai et 
al., 2011). Study quality ranged from 0.32 to 0.95. All used patient reported outcome measures, 
eight of which had been validated, with three having negligible or no evidence of validity.  
Impact of presence of diabetic retinopathy 
Diabetic retinopathy was associated with worse visual functioning in comparison to 
individuals with diabetes but not diabetic retinopathy (Pereira et al., 2017, Lamoureux et al., 2010, 
Aroney et al., 2016, Gillies et al., 2014), those with diabetes and good vision (Ratanasukon et al., 
2016) and those with other conditions including age-related macular degeneration, glaucoma, and 
cataract (Hariprasad et al., 2008) even when visual acuity was controlled for (Lin and Yu, 2012, 
Broman et al., 2002). One study however, reported uveitis to have a more debilitating impact on 
visual functioning than diabetic retinopathy (Hui et al., 2017), even after controlling for visual acuity. 
Greatest restrictions on visual functioning due to diabetic retinopathy included reading print, 
mobility, work, leisure activities (Lamoureux et al., 2004) driving a car (Bertelmann et al., 2016, 
Bressler et al., 2016), seeing faces, watching television and reading newspapers (Henricsson and 
Heijl, 1994, Nilsson, 1986). However, one study found no significant differences in visual functioning 
between a DME sample and a non-diabetic retinopathy sample or between people with diabetic 
retinopathy and individuals with low vision from other causes with equivalent visual acuity 
(Ahmadian and Massof, 2008). Two studies reported visual functioning as worse in bilateral (but not 
unilateral) diabetic retinopathy in comparison to diabetes without any diabetic retinopathy (Man et 
al., 2016, Mazhar et al., 2011). 
Impact of diabetic retinopathy severity 
People with proliferative diabetic retinopathy had significantly worse visual functioning 
compared to non-proliferative diabetic retinopathy (Gabrielian et al., 2010, Lamoureux et al., 2010). 
One study reported progression or improvement of severity in diabetic retinopathy was not 
associated with visual functioning when analysed independently of visual acuity changes (Hirai et al., 
2011). Another study showed that people with severe non-proliferative diabetic retinopathy or 
proliferative diabetic retinopathy reported more difficulties with reading and noticing objects to the 
side than people with mild or moderate non-proliferative diabetic retinopathy and no diabetic 
retinopathy even after controlling for visual acuity and DME (Willis et al., 2017). However, no 
differences in difficulty with close-up work, finding objects on a crowded shelf, walking down steps, 
stairs, or curbs, and driving were found. After controlling for potential confounders, these 
differences only remained significant when comparing severe non-proliferative diabetic retinopathy 
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and proliferative diabetic retinopathy to individuals with no diabetic retinopathy. One of the studies 
also showed visual functioning to be worse for people with DME when compared with people with 
diabetic retinopathy, but no DME (Man et al., 2016). 
Several studies reported significant associations between visual functioning and visual 
acuity; as visual acuity in people with diabetic retinopathy and those with DME became poorer, 
problems with visual functioning increased (Cetin et al., 2012, Granstrom et al., 2015, Mazhar et al., 
2011, Okamoto et al., 2008, Okamoto et al., 2010, Trento et al., 2013, Scanlon et al., 2015). Visual 
acuity in the better eye was reported to be significantly correlated with better visual functioning, 
with no association with the worse eye (Warrian et al., 2010). Trento et al. (2017) investigated visual 
functioning in mild diabetic retinopathy compared to people with diabetes but without diabetic 
retinopathy. Whilst, no significant differences were found for the majority of the visual functioning 
domains, vision specific mental health was significantly better in the diabetic retinopathy group in 
comparison to the non-diabetic retinopathy diabetes group. Vision specific role difficulties was 
significantly worse in the mild diabetic retinopathy group in comparison to the non-diabetic 
retinopathy diabetes group.  
Descriptive results 
Some included studies purely described NEI VFQ-25 scores in a sample of individuals with 
diabetic retinopathy, without a comparison group, or any further analysis. In comparison to scores of 
individuals with diabetes but no diabetic retinopathy reported in other studies (Klein et al., 2001, 
Pereira et al., 2017) people with diabetic retinopathy reported worse overall visual functioning 
(Beaulieu et al., 2016, Bressler et al., 2014, Lloyd et al., 2013, Loftus et al., 2011, Matza et al., 2008, 
Mitchell et al., 2013, Okamoto et al., 2014, Ramu et al., 2017, Toprak et al., 2005, Tsilimbaris et al., 
2013, Turkoglu et al., 2015, Vijayan et al., 2017). One descriptive study reported that people with 
DME or proliferative diabetic retinopathy had difficulties with seeing the television screen, reading 
normal print, seeing at night, and recognizing faces (Bailey and Sparrow, 2001).   
Discussion 
  Presence of diabetic retinopathy was associated with reported difficulties with instrumental 
activities of daily living (i.e. activities essential for independent living such as managing one’s own 
finances, housework and shopping); this worsened with disease severity. Some individuals with 
diabetic retinopathy also reported ceasing or reducing working. Limited evidence from objective 
performance based measures suggested that diabetic retinopathy may be associated with impaired 
mobility when considering walking, yet driving and falls risk may remain unaffected. There was 
clearer consensus however, for the association between diabetic retinopathy severity and physical 
quality of life, and this supports results of a previous review [10]. As the majority of included quality 
of life measures were generic, these may not be sensitive to the specific impact of diabetic 
retinopathy on the individual; future studies would benefit from utilising diabetic retinopathy-
specific measures such as the DME/DR item banks [16] and the RetDQoL [17].  
 The quality of life and well-being articles in this review had a strong focus on how the clinical 
characteristics of DME and diabetic retinopathy, particularly diagnosis and severity, are associated 
with these outcomes. Recent literature has however suggested that clinical characteristics are not 
the best predictors of quality of life or well-being in ophthalmic conditions. Beliefs and feelings 
about a condition, its treatment and social support are better predictors of anxiety, depression, and 
quality of life [18-20]. This suggests that psychosocial well-being and quality of life are amenable to 
change through psychosocial interventions, alongside traditional low vision services. Further 
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research is therefore needed in DME and diabetic retinopathy to establish whether these same 
relationships are present and if so to develop interventions that help support patients and improve 
their well-being. A recent systematic review and meta-analysis [21] has highlighted a lack of 
evidence on the effectiveness of psychosocial interventions in low vision and called for high-quality 
trials in the field. Trials in recent years [22, 23] have shown problem-solving treatment to be a 
potentially useful intervention for depressive symptoms in low vision.  
 Over half of included studies investigated visual functioning in diabetic retinopathy, with the 
vast majority utilising the NEI-VFQ-25. People with mild diabetic retinopathy reported little to no 
impact on visual functioning; whilst visual functioning impairment increased with diabetic 
retinopathy severity and worsening visual acuity. Diabetic retinopathy was associated with poorer 
visual functioning compared to other eye conditions, even after controlling for visual acuity. This 
suggests the impact of diabetic retinopathy on visual functioning is not due to its diminishing impact 
on visual acuity alone, but due to specific symptoms and complications related to diabetic 
retinopathy. The results indicate the potential need in clinical practice to measure and consider the 
everyday impacts of diabetic retinopathy and DME, which include psychological well-being, 
functional status, quality of life, and impacts to work. Indeed, there is a growing body of literature 
on the value of PROMs in everyday clinical practice [24-26], with the caveat that questionnaire use 
ought to be coupled with good patient-practitioner communication. 
The inconsistency within our results might arise from heterogeneous sample sizes, different 
cultural backgrounds and disease severity definitions between studies making reliable comparisons 
problematic. Furthermore, some studies did not control for or were unable to adjust for 
confounding variables in analyses, potentially biasing results. Very few articles compared the impact 
of DME to non-DME diabetic retinopathy samples [27-30], making it difficult to know of any 
potential differences between these two conditions. Further research is therefore needed.  
Our results are consistent with those of previous reviews. One non-systematic review [9] 
published over ten years ago also reports reduced quality of life as a result of diabetic retinopathy.  
In a systematic review from Fenwick et al [10] quality of life was reported to be worst affected in the 
vision-threatening stages of diabetic retinopathy; this was seen in our systematic review with 
proliferative diabetic retinopathy associated with worst quality of life. Chen et al [11] reviewed the 
humanistic burden of DME in the USA and selected European countries and included two articles 
reviewed in this systematic review [31, 32]. Their findings suggested that DME may be associated 
with increased economical and societal costs. However, conclusions were limited by scarcity of 
evidence at the time. Whilst our results benefit from a greater wealth of evidence overall, studies 
focussing specifically on DME remain scarce. Finally, the most recent review by Fenwick et al [33] 
concluded that diabetic retinopathy may have a considerable impact on psychological well-being. 
The authors called for more large scale studies to be conducted, with increased consistency in 
methodology. More than half of the studies included in our review were however published since 
this, and whilst several included large sample sizes, there remains little consistency across study 
methodology.  
It is important to consider these findings in light of the limitations of this review. Firstly, only 
articles published in peer-reviewed journals were included, which may have influenced the results 
due to submission and/or publication bias. Due to lack of translation resources, papers that were not 
published in English were excluded. The quality of any systematic review is in part based on the 
quality of the included studies, which in the case of this review was mixed. One of the limitations of 
this is review is that we did not discriminate between articles of lower quality and those of higher 
quality. Also, the review did not include studies with qualitative methodologies (e.g. studies from 
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Devenney et al. [34], Fenwick et al. [35], and Coyne et al. [36]), such studies have the potential to 
provide rich insights into the impact of having DR/DME and ought to be the subject of a future 
review. A further limitation relates to the multiple categories under which results are arranged. In 
reality, all of these categories fall under the broader holistic construct of quality of life. Furthermore, 
there is some overlap between the categories used in this review. For example, some of the results 
in the visual functioning section relate to psychological well-being, and some items within the IVI 
and NEI VFQ-25 relate to health-related quality of life. However, we have attempted to organise 
results according to their main outcome, based on the categories presented in existing research 
literature [15]. Finally, it is likely that individuals taking part in research studies and clinical trials may 
be in better health than a random sample of the population. This could be remedied by only 
including studies using routinely collected data from medical records. Given that data on QoL etc. is 
not currently routinely collected in clinics this is not possible at this time. It is therefore possible that 
our results underestimate the scale of the issues described here. 
This systematic review supplements existing literature by providing an extensive 
investigation of the impact of DR/DME. Diabetic retinopathy was found to have a considerable 
impact on visual functioning, which is more impaired in individuals with greater disease severity. The 
research indicates that diabetic retinopathy has the potential to limit activities including working, 
driving, walking and reading, and thus limiting autonomy in life. Vision loss in diabetic retinopathy 
was associated with greater frequency of depressive symptoms and poorer quality of life. Although 
this review has its limitations it is the first to synthesise the literature across a range of patient-
centred outcomes in diabetic retinopathy, and as such has allowed previously unanswered questions 
to be addressed as well as identifying important gaps in the literature.  
Our results hint at several further implications for future research. A wide range of tools 
were used for each domain, making cross-comparisons between studies in this review difficult. 
Moreover, a number of studies used unvalidated questionnaires. The issue of inconsistency in 
PROMs has been cited as a substantial challenge to overcome in maximising the impact of PROMs 
(37). We suggest that future research takes steps to address this, by providing evidence for the most 
appropriate tool for use in DR, including involvement of individuals with diabetic eye disease from 
the start of and throughout the PROM design process [38], and educating clinicians and researchers 
in the importance of appropriate PROM selection when designing studies and clinical trials. This 
might require an overhaul of traditional PROM delivery, for example use of computerised adaptive 
testing and item banking [16], or complementing PROMs with objective performance based 
measures of visual performance. Only two studies included in this review objectively measured 
performance of everyday tasks in diabetic retinopathy. It is well evidenced that this type of outcome 
complements patient-reported outcomes and provides additional information on the impact of eye 
disease, as well as being less susceptible to cultural and literacy barriers [39-42]. Future research in 
this field ought to substantiate this review’s findings relating to everyday visual functioning in DR 
using performance based measures.  
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